

F6S Recognizes Elixira as #1 in '9 top Nanotechnology companies and startups in Sweden in October 2025'

Elixira, a Swedish cancer prevention innovation invented and founded by Tess Fries, achieves #1 placement in F6S's latest ranking of nanotechnology companies in Sweden for the second time.



Lund, Skane Oct 22, 2025 ([Issuewire.com](https://www.issuewire.com)) - According to a recent listing by F6S, one of the world's largest startup and innovation communities, Elixira has been recognized as #1 in "9 top nanotechnology companies and startups in Sweden in October 2025," marking the second consecutive month of #1

ranking—September and October. In addition, Elixira is also ranked #1 in the F6S “8 top Life Sciences companies and startups in Sweden in October 2025” category and #11 in the global “100 top Nanotechnology companies and startups in October 2025” list.

The recognition comes approximately seven months after the patent filing on 27 March 2025, highlighting the steady international traction of Elixira’s preventive nanomedicine technology.

Founded and invented by Tess Fries, Elixira represents a new frontier in nanomedicine—an AI-guided nanobot platform designed as a one-time injection for lifelong, autonomous cancer prevention. The patent-pending system integrates nanotechnology, artificial intelligence, and hybrid energy harvesting into a fully self-sustaining medical platform.

“Being listed as Sweden’s top nanotechnology company is a great honor and an important recognition,” said Tess Fries, inventor & founder of Elixira. “Elixira’s mission is focused: to make cancer prevention available across borders and free to patients. Elixira integrates existing technologies and peer-reviewed research that have already made this possible since 2020. A detailed technical feasibility report with over 100 peer-reviewed scientific sources is available to prospective partners under NDA.”

About Elixira

Elixira is a Swedish nanomedicine platform designed to enhance the immune system and autonomously detect and eliminate cancer cells across all cancer types. The technology’s technical feasibility was independently evaluated by a leading European Contract Research Organization (CRO) in 2025.

About F6S

F6S is a leading global platform headquartered in London, connecting founders and startups with funding, accelerators, and growth opportunities. With a community of more than 5.9 million founders and startups worldwide, F6S empowers entrepreneurs to scale innovation and build the companies shaping our future.

Official Links

[Elixira | F6S](#)

[Elixira | Crunchbase](#)

[Elixira | LinkedIn](#)

[Elixira | Facebook](#)

[Tess Fries | LinkedIn](#)

Media Contact

Elixira

*****@elixira.tech

+46 76 199 76 97

Source : Elixira

[See on IssueWire](#)